gaining momentum in gene therapy - ois...ois@asrs. forward-looking statements statements contained...
TRANSCRIPT
![Page 1: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/1.jpg)
Gaining Momentum in Gene Therapy
July 25, 2019
OIS@ASRS
![Page 2: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/2.jpg)
Forward-looking Statements
Statements contained in this document regarding matters, events, statistics, or clinical or financial results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding plans and milestones related to Adverum’s product candidates, clinical studies, and regulatory filings, the therapeutic and commercial potential of Adverum’s product candidates and the sufficiency of Adverum’s resources to fund lead programs, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate under the circumstances. Adverum may not consummate any of these plans or these product, clinical development or regulatory goals in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies, risks and uncertainties inherent in the product development and the regulatory approval process, the risk that Adverum will not be able to successfully develop or commercialize any of its product candidates and the risk that Adverum will be delayed in receiving or fail to receive required regulatory approvals. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the SEC, including its Form 10-Q filed with the SEC on May 8, 2019, particularly in the section titled “Risk Factors.” All forward-looking statements contained in this document speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This document contains estimates, projections and other information concerning Adverum’s industry, business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, Adverum obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, and should not be construed as representations made by, Adverum.
2
![Page 3: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/3.jpg)
Adverum is a Clinical-stage Gene Therapy Company with
Industry-leading Expertise
3
Leadership team with extensive industry expertise
Industry-leading AAV platform and capabilities:▪ Next-generation vectors
▪ Robust patent portfolio
▪ Scalable manufacturing process
ADVM-022, single-injection gene therapy candidate targeting wet AMD:▪ First intravitreally-delivered gene therapy for wet AMD utilizing proprietary AAV.7m8 vector
▪ OPTIC Phase 1 trial evaluating ADVM-022 in patients with wet AMD
▪ OPTIC 24-week primary and secondary endpoint data from first cohort (n=6) to be presented at
Retina Society 9/2019
~$189.5M in cash* to fund operations into 2021
*Cash, cash equivalents, and short-term investments as of March 31, 2019 (unaudited).
![Page 4: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/4.jpg)
Phase 2Phase 1PreclinicalResearch
4
Advancing Gene Therapies for Ocular and Rare Diseases
Gene Therapy Candidate
ADVM-022
Rare Disease
Rare Disease
Programs – Worldwide Rights
OPTIC Trial for Wet Age-related Macular Degeneration (AMD)
Hereditary Angioedema (HAE)
Alpha-1 Antitrypsin (A1AT) Deficiency
Up to 5 Undisclosed Targets
X-linked Retinoschisis+3 Undisclosed Targets
Partnered Programs
Inherited Retinal Disease
Ophthalmic Disease
Additional VEGF-driven Retinal
Diseases
![Page 5: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/5.jpg)
5
ADVM-022: Gene Therapy Designed to Provide Long-term Anti-VEGF Treatment with a
Single Intravitreal Injection
› Single intravitreal injection of ADVM-022 to provide sustained
delivery of standard-of-care anti-VEGF protein
› Proprietary AAV.7m8 vector and promoter sequences
› Broad patent protection
› FDA Fast Track Designation for wet AMD
› Long-term efficacy demonstrated in NHPs comparable to an
anti-VEGF standard-of-care therapy
› Robust protein levels measured in non-human primate (NHP)
vitreous humor up to 30 months post injection✓
› Long-term safety demonstrated: Normal retinal structure and
function is maintained out to 30 months in NHPs post injection✓
![Page 6: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/6.jpg)
6
Single Injection of ADVM-022 in NHPs Shows Efficacy
13 Months Post Injection Comparable to Standard-of-Care
40%
5%6%
0%
10%
20%
30%
40%
50%
Vehicle(n=8 eyes)
Aflibercept(n=8 eyes)
ADVM-022(n=8 eyes)
% G
rad
e IV
CN
V L
esio
ns
* p < 0.0001 vs. vehicle
ADVM-022 Long-term Efficacy(AAV.7m8-aflibercept)
**
13 months post-injection
(2x1012 vg/eye)
Source: Grishanin, et al. ”Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.” Molecular Therapy. 2019.
DOI:https://doi.org/10.1016/j.ymthe.2018.11.003
NHP = Non-human primates
Administered at time of lesion
![Page 7: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/7.jpg)
7
Single IVT ADVM-022: Long-Term Sustained Aflibercept
Expression Levels Comparable to Aflibercept-injected Eyes
ADVM-022 Sustained Expression in Vitreous
up to 21 Months
ADVM-022 Sustained Expression in Vitreous and
Aqueous Humor 30 Months Post Injection
› ADVM-022 induces robust and persistent
aflibercept expression in the vitreous over the
21-month study in lasered and non-lasered eyes
› At 30 months post-injection of ADVM-022,
pharmacologically-relevant levels of aflibercept
were induced in the vitreous and aqueous humor
Source: Oral presentation, American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting, May 2019
NHP = Non-human primates
2 x 1012 vg/eye. N=3 animals; both eyes injected at t=0 2 x 1012 vg/eye. N=1 animal; both eyes injected at t=0
* Time after IVT bolus of aflibercept protein (1.2 mg/eye) when similar aflibercept levels were observed in NHPs (Grishanin et al, ESGCT 2018)
25 days post-bolus
aflibercept*
38 days post-bolus
aflibercept*
21 days post-bolus
aflibercept*
26 days post-bolus
aflibercept*
![Page 8: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/8.jpg)
8
ADVM-022 Induced Aflibercept Levels in NHPs within
Therapeutic Window for Standard-of-care Aflibercept
Treatment
Aflibercept Levels in Vitreous Humor
ADVM-022 vs. Aflibercept Bolus (1.2mg)
Source: Poster presentation, American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting, May 2018
NHP = Non-human primates
› Levels of vector-derived aflibercept
measured in the vitreous humor 56 days
post ADVM-022 injection match levels of
aflibercept recombinant protein 3-4
weeks post-bolus of protein injection
› Measured levels are within the duration
of action for aflibercept0 .1
1
1 0
1 0 0
D a y
Afl
ibe
rc
ep
t (
g/m
L)
A flib e rc e p t, 1 .2 m g /e y e b o lu s
1 7 1 4 2 8 4 2 5 6
A D V M -0 2 2 , 2 x 1 012
v g
6 .8 g /m L
Aflibercept 1.2mg/eye
(n=4 eyes / measurement)
ADVM-022 2x1012 vg/eye
(n=4 eyes)
![Page 9: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/9.jpg)
Long-term Expression of Aflibercept in Retina from
ADVM-022 Does Not Affect Retinal Morphology
9
OCT sections of retinas from NHP IVT injected with
ADVM-022 (2 x 1012 vg/eye) at baseline and 30 months post-dose
Source: Oral presentation, American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting, May 2019
![Page 10: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/10.jpg)
10
Normal ERG Responses upon Sustained Expression of
Aflibercept in NHP Eyes Dosed with ADVM-022
Full field scotopic ERG in vehicle and ADVM-022
treated eyes 19 months post-dose
Multifocal ERG in ADVM-022 treated eyes
30 months post-dose
› No significant difference
between vehicle and
ADVM-022 groups
observed› Treated eyes 30 months post-dose is
within normal mfERG response limits
Source: Oral presentation, American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting, May 2019
NHP = Non-human primates
ERG = Electroretinography
![Page 11: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/11.jpg)
11
Baseline assessment Treatment evaluation Follow-up
Day 1 244 8 12 16 20
Primary endpoint
(Safety) 24 weeks
104
Secondary endpoints (Efficacy)
Anti-VEGF rescue therapy administered if retreatment criteria met
Weeks
Cohort 2:
2x1011 vg
n=6
Cohort 1:
6x1011 vg
n=6
OCT = Optical Coherence Tomography
Screening
Aflibercept
Injection
SD-OCT
Assessment
ADVM-022 Injection
ADVM-022 OPTIC Phase 1 Trial for Wet AMD
Initiated 4Q18, Currently Enrolling Cohort 2
Prophylactic oral corticosteroid taper
(13 days total)
✓ DMC
Safe to
Proceed
Additional
cohort, if
needed
Assess
tolerability
and efficacy
• Change in BCVA at 24 weeks
• Change in CRT at 24 weeks
• Anti-VEGF rescue injections
through 104 weeks
![Page 12: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/12.jpg)
12
Upcoming Corporate Milestones
*Cash, cash equivalents, and short-term investments as of March 31, 2019 (unaudited).
ADVM-022 for Wet AMD
✓ Dosed first patient in OPTIC phase 1 cohort 2 at 2x1011 vg/eye 6/2019
OPTIC phase 1 data from first cohort to be presented at The Retina Society 52nd Annual
Meeting9/2019
Rare Disease Programs
Update on programs Mid-Y19
In-house Manufacturing Capabilities
Occupy new facility with expanded in-house process development capabilities to 1000L YE19
~$189.5M in cash* to fund operating expenses and capital expenditures into 2021
![Page 13: Gaining Momentum in Gene Therapy - OIS...OIS@ASRS. Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial](https://reader034.vdocuments.us/reader034/viewer/2022042412/5f2c833f9b61454a771d0d4f/html5/thumbnails/13.jpg)
Nasdaq: ADVM